pic
Koronis Pharma, Inc. develops antiviral therapeutics based on Viral Decay Acceleration™ (VDA) - a novel drug mechanism. The Company's lead product candidate is KP-1461 for the treatment of HIV.
  • Viral Decay Acceleration exploits the strength of a virus – its high mutation rate – to target its collapse. Learn more
  • Stay Informed by joining our email distribution list to receive the latest announcements from Koronis, including company alerts and press releases.

Revolutionizing HIV Therapeutics

Viral Decay Acceleration™ Animation

Viral Fitness & Mutagenesis Animation

To view the Flash video in fullscreen
click the Fullscreen icon in the player.